Allurion shares are trading higher after the company announced the publication of a study showing an average lean mass gain of 5.6% in patients and an average weight loss of 14% at four months on the Allurion Program.
Portfolio Pulse from Benzinga Newsdesk
Allurion shares are trading higher following the publication of a study that reported an average lean mass gain of 5.6% and an average weight loss of 14% in patients after four months on the Allurion Program.
June 20, 2024 | 3:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Allurion shares are experiencing a positive price movement due to a study showing significant health benefits from the Allurion Program, including a 5.6% gain in lean mass and 14% weight loss over four months.
The study results are likely to boost investor confidence in Allurion's product efficacy, leading to increased demand for its shares. The significant health benefits reported in the study are a strong positive indicator for the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100